P617

MOLECULAR TYPING OF *MYCOPLASMA GENITALIUM* SHOWS A DIVERSE EPIDEMIC WITH LIMITED AZITHROMYCIN RESISTANCE IN SOUTH AFRICA

¹Jolein Laumen, ¹Lieke Van Alphen, ²Liteboho Maduna, ³Andrew Medina-Marino, ⁴James McIntyre, ⁵Jeffrey Klausner, ⁶Marleen Kock, ⁶Remco Peters*. ¹Maastricht University Medical Center (MUMC), Medical Microbiology, Care and Public Health Research Institute (CAPHRI), Maastricht, Netherlands; ²University of Pretoria, Pretoria, South Africa; ³Foundation for Professional Development, Pretoria, South Africa; ⁴Anova Health Institute, Johannesburg, South Africa; ⁵UCLA David Geffen School of Medicine and Fielding School of Public Health, Epidemiology, Los Angeles, USA; ⁶University of Pretoria, Medical Microbiology, Pretoria, South Africa

10.1136/sextrans-2019-sti.685

Background The occurrence of azithromycin resistance in *M. genitalium* infection is unknown in Africa, where diagnostic resources are limited and STIs are managed syndromically. This study aims to gain insight in the molecular epidemiology including antimicrobial resistance of *M. genitalium* infection in South Africa.

Methods We collected 87 *M. genitalium*-positive samples obtained from participants in three study cohorts: HIV-infected pregnant women residing in townships in Pretoria (n=44), men and women accessing primary healthcare services in rural Mopani District (n=32), and men accessing sexual health services in Johannesburg (n=11). Molecular typing was performed using single nucleotide polymorphism (SNP) analysis of the MG191 gene to determine sequence type (ST) combined with variable-number of tandem-repeat (VNTR) assessment of the MG309 gene. Molecular detection of macrolide resistance-associated mutations in the 23S rRNA gene was done and, if detected, subsequent sequencing of the *parC* and *gyrA* genes for quinolone resistance.

Results SNP analysis was successful in 22 specimens and showed 17 different STs (9 known and 8 new STs). VNTR assessment was successful for 36 specimens and showed variation in the number of repeat, ranging from 8 to 19; four strains had the same number of repeats (11). There was no geographic clustering of specific STs or number of repeats observed. Azithromycin resistance was detected in only 1/87 specimens (1.1%); a mutation in the *parC* gene associated with quinolone resistance was also detected in this case. This specific strain was a unique novel ST, but with similar tandem repeats, compared to the drug-susceptible stains.

Conclusion This study shows a well-established, genetically diverse epidemic of *M. genitalium* infection in South Africa. The prevalence of azithromycin resistance was low, which is probably the result of the relatively recent introduction of azithromycin in the syndromic management guidelines. Nevertheless, introduction of diagnostics and surveillance of resistance is urgently warranted.

Disclosure No significant relationships.

P618

MYCOPLASMA GENITALIUM TESTING IN CLINICAL PRACTICE: PREVALENCE AND RESISTANCE RATES IN A SOUTH LONDON SEXUAL HEALTH CLINIC

¹Emma Wallis*, ¹Lisa Hamzah, ²Achyuta Nori. ¹Guy's and St Thomas' NHS Trust, Burrell Street Sexual Health Centre, London, UK; ²Guy's and St Thomas's NHS Foundation Trust, London, UK

10.1136/sextrans-2019-sti.686

Background The British Association of Sexual Health and HIV recommends testing for *Mycoplasma genitalium* (MG) in clinically indicated conditions (CIC) (non-gonococcal urethritis (NGU); epididymitis; pelvic inflammatory disease (PID); contacts of MG; test of cure (TOC)). MG testing was implemented in September 2018 in a large urban sexual health service. We aimed to assess the prevalence and antimicrobial resistance of MG in this clinic population after a 6-weeks embedding period.

Methods All patients diagnosed with a CIC and tested for MG between 28/10/2018-18/12/2018 were included. MG testing was performed using Aptima *Mycoplasma genitalium* assay (AMG; Hologic); confirmatory testing and resistance testing for macrolides and fluoroquinolones was performed at the Public Health England reference laboratory.

Results The 371 individuals tested for MG were predominantly male (77%), heterosexual (78%) and Caucasian (46%) and 85% tested per guidance. 18% were positive for MG. 38% (25/65) were positive using AMG but had negative confirmatory test and no resistance results. 18% with MG were co-infected with another sexually transmitted infection (9 chlamydia; 2 gonorrhoea; 2 trichomonas). The prevalence of MG by testing indication was: contacts of MG (33%, 11/33), TOC (25%, 3/12), NGU/epididymitis (17%, 38/229), PID/cervicitis (11%, 5/44) and inappropriately tested (14%, 7/51). 38% of MG had resistance; 34% macrolides; 8% fluoroquinolones; 3% both. Macrolide resistance was identified on the 23S rRNA gene at loci A2058G (45%) and A209G (55%), all fluoroquinolone was on the *parC* gene.

Conclusion We report a high MG prevalence in this population with high rates of resistance, the majority of which is macrolide. We recommend resistance guided therapy in view of high macrolide and fluoroquinolone resistance. Positive RNA detection with negative DNA detection is concerning and may either represent very low bacterial loads, a biological false positive result of AMG or a false negative result of the confirmatory test.

Disclosure No significant relationships.

P619

MACROLIDE AND QUINOLONE RESISTANCE IN MYCOPLASMA GENITALIUM: DATA FROM A UK SEXUAL HEALTH CLINIC

¹Ruairi Conway*, ¹Seamus Cook, ²Cassandra Malone, ²Mohammed Osman Hassan-Ibrahim, ³Suneeta Soni. ¹Brighton and Sussex Medical School, Brighton, UK; ²Brighton and Sussex University Hospitals NHS Trust, Microbiology and Infection, Brighton, UK; ³Brighton and Sussex University Hospitals NHS Trust, GU/HIV, Brighton, UK

10.1136/sextrans-2019-sti.687

Background Rates of macrolide resistance (MR) in *Mycoplasma genitalium* (Mgen) globally remain alarmingly high (30-100%) and quinolone resistance (QR) is now an increasing concern. In the UK, testing for Mgen is in its infancy and data for MR and QR are therefore lacking. The recent publication of guidelines by British Association for Sexual Health and HIV (BASHH) delivers hope that testing and experience in managing Mgen infection will increase. We aimed to measure infection rates and to determine the prevalence of MR and QR in men with urethritis and women with pelvic inflammatory disease (PID) attending a UK sexual health clinic.